Health & Fitness Doctors successfully treat rare J&J blood clot, case report shows

00:25  06 may  2021
00:25  06 may  2021 Source:   livescience.com

Link found between cannabis and rebound headaches after migraine

  Link found between cannabis and rebound headaches after migraine The early data suggest a link, but cannot say whether cannabis causes the rebound headaches.However, though a link has been uncovered, it's still unclear whether cannabis directly triggers the rebound headaches, the study authors told Live Science. The study also didn't specify what types of cannabis products the patients used, so it's unknown whether certain products show a greater correlation to rebound headaches than others.

Doctors have successfully treated a patient who developed very rare blood clots after receiving the Johnson & Johnson COVID-19 vaccine in early April using an alternative to heparin, which is a blood thinner experts advised against using, according to a new case report.

An illustration of a bloostream with platelets, red blood cells and white blood cells. © Provided by Live Science An illustration of a bloostream with platelets, red blood cells and white blood cells.

The Centers for Disease Control and Prevention (CDC) briefly paused — and since restarted — the use of the single-dose Johnson & Johnson COVID-19 vaccine on April 13 to investigate several cases of a rare clotting disorder that occured after vaccination.

Immune response may explain rare clots after AstraZeneca vaccine

  Immune response may explain rare clots after AstraZeneca vaccine German researchers studied nine shot recipients who developed clots. They found signs that the shot triggers platelet-attacking antibodies that lead to misguided blood clotting.Two separate research teams in Germany and Norway found the shot can in very rare cases cause the body to attack its own blood platelets, triggering deadly clots in the brain.

The pause was, in part, to make sure that doctors knew how to treat patients who developed a blood-clotting disorder known as thrombosis with thrombocytopenia syndrome (TTS) or vaccine-induced thrombotic thrombocytopenia (VITT). This rare syndrome involves blood clots in the veins of the brain and very low platelet counts.

Related: Quick guide: COVID-19 vaccines in use and how they work

Typically, hospitals treat blood clots with a blood thinner known as heparin. But because heparin can, very rarely, cause an autoimmune reaction that leads to similar problems, including low platelet counts, the CDC recommended against using the blood thinner to treat VITT. But there were no specific recommendations for alternative medications, according to the report.

People waiting for first jab are NOT put off by blood clot fears

  People waiting for first jab are NOT put off by blood clot fears Concerns about highly-rare clots have done nothing to deter those waiting for their first dose of the vaccine. Here, Britons tell how they would 'snap someone's hand off' for the jab.A review by the drugs watchdog the MHRA found that by the end of March, 79 out of 20million Britons vaccinated with the AstraZeneca vaccine had suffered blood clots in the brain or arteries, a rate of about one in 250,000.

In this case, a healthy 40-year-old white female patient was given the Johnson & Johnson vaccine in early April; five days after vaccination, she developed a headache, sinus pressure, muscle pain and a sore throat; eight days after vaccination, she went to an urgent care center and was prescribed antibiotics, corticosteroids and muscle relaxants.

Gallery: 10 of the strangest medical cases (Live Science)

But her headaches worsened, especially with movement, and she developed dizziness and light sensitivity, so she went to the UCHealth University of Colorado Hospital 12 days after receiving the vaccine. Doctors diagnosed her with VITT, and she was treated with the blood thinner bivalirudin. After receiving the medication, her platelet counts steadily increased, and she was discharged from the hospital six days later. Her clots and headaches also disappeared and her platelet counts had increased even more when doctors followed up with her three days later.

"A single patient treated with bivalirudin for suspected VITT subsequently experienced symptom improvement, a rise in platelet count, and did not demonstrate any immediate negative outcomes," the authors wrote. "A provider may consider bivalirudin as an alternative to heparin in patients with suspected VITT following [Johnson & Johnson] Vaccination, pending more definitive research."

Similar rare blood clotting events have occured with the Oxford-AstraZeneca vaccine.

“Our experience shows us that these clot reactions are very rare, but they can be treated,” lead co-author Dr. R. Todd Clark, an assistant professor of emergency medicine at the University of Colorado School of Medicine, said in a statement. “Americans can feel comfortable getting vaccinated and should discuss any vaccination concerns with their doctor."

Getting vaccinated is a "critical step" in fighting this pandemic and returning to our normal lives, he added.

The findings will appear in the journal Annals of Emergency Medicine.

Originally published on Live Science.

Doctors discover blood thinner that can dissolve vax-linked clots .
Doctors saved the life of Morgan Wolfe, 40, from Aurora, Colorado after she developed blood clots following the Johnson & Johnson vaccination after they used an alternative blood thinner,Morgan Wolfe, 40, from Aurora, received the one-dose shot on April 1. Soon after, she began experiencing a headache, dizziness and changes to her vision.

usr: 1
This is interesting!